Entera Bio Ltd. (ENTX) and Opko Health Inc. (OPK) announced encouraging pharmacokinetic and pharmacodynamic findings from their joint research on oral Oxyntomodulin (OXM) for combating obesity and metabolic disorders.
OXM, a naturally occurring peptide hormone present in the small intestine, helps suppress appetite and induce weight loss. It is being evaluated as a potential once-daily therapeutic solution for individuals suffering from obesity, metabolic dysfunctions, and fibrotic conditions.
In a proof of concept study conducted with rodent and pig models, oral OXM exhibited significant systemic exposure, a favorable pharmacokinetic profile, and promising bioavailability.
The research further showed that the administration of oral OXM resulted in a statistically significant reduction in plasma glucose levels following glucose administration, compared to a placebo, during a glucose tolerance test in rats.
"These bioavailability and pharmacological data bolster our efforts towards IND-enabling activities for this program," stated Miranda Toledano, CEO of Entera.
As of now, Entera's stock has declined by 3.06%, trading at $1.90 on the Nasdaq.
